Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

by Mansfield, A.S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., Liu, S.V., Horn, L., Wen, X., Quach, C., Yu, W., Kabbinavar, F., Lam, S., Morris, S., Califano, R.
Published in Annals of oncology

IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

by Califano, R., Każarnowicz, A., Karaseva, N., Sánchez, A., Liu, S.V., Horn, L., Quach, C., Yu, W., Kabbinavar, F., Lam, S., Mansfield, A.
Published in Annals of oncology

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an o...

by Thatcher, Nick, Prof, Hirsch, Fred R, Prof, Luft, Alexander V, MD, Szczesna, Aleksandra, MD, Ciuleanu, Tudor E, Prof, Dediu, Mircea, MD, Ramlau, Rodryg, Prof, Galiulin, Rinat K, MD, Bálint, Beatrix, MD, Losonczy, György, Prof, Kazarnowicz, Andrzej, MD, Park, Keunchil, MD, Schumann, Christian, Prof, Reck, Martin, MD, Depenbrock, Henrik, MD, Nanda, Shivani, MS, Kruljac-Letunic, Anamarija, PhD, Kurek, Raffael, MD, Paz-Ares, Luis, MD, Socinski, Mark A, Prof
Published in The lancet oncology

49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC)

by Califano, R, Każarnowicz, A, Karaseva, N, Sánchez, A, Liu, S V, Horn, L, Quach, C, Yu, W, Kabbinavar, F, Lam, S, Mansfield, A
Published in Annals of oncology

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

by Davies, Christina, Dr, Pan, Hongchao, PhD, Godwin, Jon, DPhil, Gray, Richard, Prof, Arriagada, Rodrigo, Prof, Raina, Vinod, Prof, Abraham, Mirta, MD, Alencar, Victor Hugo Medeiros, MD, Badran, Atef, PhD, Bonfill, Xavier, MD, Bradbury, Joan, Clarke, Michael, Prof, Collins, Rory, Prof, Davis, Susan R, Prof, Delmestri, Antonella, PhD, Forbes, John F, Prof, Haddad, Peiman, Prof, Hou, Ming-Feng, Prof, Inbar, Moshe, Prof, Khaled, Hussein, Prof, Kielanowska, Joanna, MD, Kwan, Wing-Hong, MD, Mathew, Beela S, MD, Mittra, Indraneel, Prof, Müller, Bettina, MD, Nicolucci, Antonio, MD, Peralta, Octavio, MD, Pernas, Fany, Petruzelka, Lubos, Prof, Pienkowski, Tadeusz, Prof, Radhika, Ramachandran, MD, Rajan, Balakrishnan, MD, Rubach, Maryna T, MD, Tort, Sera, MD, Urrútia, Gerard, MD, Valentini, Miriam, MD, Wang, Yaochen, MD, Peto, Richard, Prof
Published in The Lancet (British edition)

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

by Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N.V., Armstrong, J., Byrne, N., Shire, N., Jiang, H., Goldman, J.
Published in Journal of thoracic oncology

Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results

by Quoix, E., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., Ottensmeier, C., Szczesna, A., Kazarnowicz, A., Beck, J.T., Westeel, V., Felip, E., Debieuvre, D., Madroszyk, A., Lacoste, G., Tavernaro, A., Bastien, B., Palanche, T., Limacher, J., Lena, H.
Published in Annals of oncology

Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study: PL02.11

by Paz-Ares, L, Chen, Y, Reinmuth, N, Hotta, K, Trukhin, D, Statsenko, G, Hochmair, M J, Özgüroğlu, M, Ji, J H, Voitko, O, Poltoratskiy, A, Ponce, S, Verderame, F, Havel, L, Bondarenko, I, Kazarnowicz, A, Losonczy, G, Conev, N V, Armstrong, J, Byrne, N, Shire, N, Jiang, H, Goldman, J
Published in Journal of thoracic oncology

1055PDTIME, A PHASE 2B/3 STUDY EVALUATING TG4010 IN COMBINATION WITH FIRST LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC). PHASE 2B RESULTS

by Quoix, E, Losonczy, G, Forget, F, Chouaid, C, Papai, Z, Gervais, R, Ottensmeier, C, Szczesna, A, Kazarnowicz, A, Beck, J.T, Westeel, V, Felip, E, Debieuvre, D, Madroszyk, A, Lacoste, G, Tavernaro, A, Bastien, B, Palanche, T, Limacher, J, Lena, H
Published in Annals of oncology

918 The role of patients and doctors in making decisions about the choice of the kind of adjuvant treatment in early breast cancer

by Jagiello-Gruszfeld, A., Szybicka-Flisikowska, E., Wachula, E., Sikorska, M., Kazarnowicz, A., Adamowska, R., Gugala, K., Godlewski, J.
Published in European journal of cancer supplements

Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall...

by Grenda, Anna, Krawczyk, Paweł, Kucharczyk, Tomasz, Błach, Justyna, Reszka, Katarzyna, Chmielewska, Izabela, Buczkowski, Jarosław, Kieszko, Robert, Siwiec, Jan, Kubiatowski, Tomasz, Bożyk, Aleksandra, Krukowska, Kinga, Jarosz, Bożena, Paśnik, Iwona, Pankowski, Juliusz, Świniuch, Daria, Stencel, Katarzyna, Gil, Michał, Lew, Kinga, Ramlau, Rodryg, Szczęsna, Aleksandra, Fidler, Sebastian, Sieracki, Andrzej, Każarnowicz, Andrzej, Serwatowski, Piotr, Grodzki, Tomasz, Milanowski, Janusz
Published in Oncology letters

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number

by Szutowicz-Zielińska, Ewa, Konopa, Krzysztof, Kowalczyk, Anna, Suszko-Każarnowicz, Małgorzata, Duchnowska, Renata, Szczęsna, Aleksandra, Ratajska, Magdalena, Sowa, Aleksander, Limon, Janusz, Biernat, Wojciech, Burzykowski, Tomasz, Jassem, Jacek, Dziadziuszko, Rafał
Published in Oncotarget

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, p...

by Quoix, Elisabeth, Prof, Lena, Hervé, MD, Losonczy, Gyorgy, Prof, Forget, Frédéric, Prof, Chouaid, Christos, Prof, Papai, Zsolt, Prof, Gervais, Radj, MD, Ottensmeier, Christian, Prof, Szczesna, Aleksandra, Prof, Kazarnowicz, Andrzej, MD, Beck, Joseph T, MD, Westeel, Virginie, Prof, Felip, Enriqueta, Prof, Debieuvre, Didier, MD, Madroszyk, Anne, MD, Adam, Julien, MD, Lacoste, Gisèle, MD, Tavernaro, Annette, MSc, Bastien, Bérangère, MSc, Halluard, Céline, MSc, Palanché, Tania, PhD, Limacher, Jean-Marc, MD
Published in The lancet oncology

Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer

by Langer, Corey J, Albert, Istvan, Ross, Helen J, Kovacs, Peter, Blakely, L. Johnetta, Pajkos, Gabor, Somfay, Attila, Zatloukal, Petr, Kazarnowicz, Andrzej, Moezi, Mehdi M, Schreeder, Marshall T, Schnyder, Judy, Ao-Baslock, Ada, Pathak, Ashutosh K, Berger, Mark S
Published in Lung cancer (Amsterdam, Netherlands)

Cardiac tamponade as the first symptom of lung cancer

by Gromadziński, Leszek, Przelaskowski, Piotr, Januszko-Giergielewicz, Beata, Górny, Jerzy, Stankiewicz, Aleksander, Każarnowicz, Andrzej, Pruszczyk, Piotr
Published in Advances in respiratory medicine

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

by Yang, J.C.-H., Park, K., Kim, J.-H., Chen, Y.-M., Chouaid, C., Feng, J.-F., Lu, S., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Planchard, D., Ignatius Ou, SaiHong, Planchard, David, Schuler, Martin, Chand, Vikram, Rohr, Klaus, Martin, Claudio Marcelo, Zarba, Juan Jose, Richardet, Martín, Mainwaring, Paul, Greil, Richard, Humblet, Yves, Bustin, Frédérique, Galdermans, Danny, Lambrechts, Marc, Vercauter, Piet, Wang, Jin, Huang, Cheng, Wu, Yilong, Cheng, Ying, Qin, Shukui, Zhang, Yiping, Lu, Shun, Garicochea, Bernardo, Alanko, Tuomo, Cadranel, Jacques, Chouaid, Christos, Zalcman, Gérard, Perol, Maurice, Fournel, Pierre, Gervais, Radj, Rotarski, Maciej, Thomas, Michael, Keilholz, Ulrich, Laack, Eckart, Strausz, Janos, Sarosi, Veronika, Jain, Minish, Venkatesan, Srinivasan, Sharma, Lalit, Dadhich, Hemant, Nagarkar, Rajnish Vasant, Gottfried, Maya, Stemmer, Solomon, Migliorino, Maria Rita, Grossi, Francesco, Gridelli, Cesare, Milandri, Carlo, Platania, Marco, Delgado, Francisco Gutierrez, Baca, Othon Padilla, Dingemans, A.M.C., Herder, G.J.M., Gans, S.J.M., Salas Sánchez, Jorge Fernando, Pantigoso, Wilbert Rodriguez, Palomino, Osbert Luis Mejia, Kazarnowicz, Andrzej, Jassem, Jacek, Lubennikov, Vladimir, Karaseva, Nina, Ragulin, Yuri, Garrido, Pilar, González Larriba, José Luis, Camps, Carlos, Campelo, Rosario García, Cobo, Manuel, Felip, Enriqueta, Kim, Dong-Wan, Kim, Joo-Hang, Han, Ji-Youn, Kim, Young-Chul, Yang, Chih-Hsin, Hsia, Te-Chun, Tsai, Ying-Huang, Tsao, Thomas Chang-Yao, Ho, Ching-Liang, Vinnyk, Yuriy, Popovych, Oleksandr, Ponomarova, Olga, Bondarenko, Igor, Shah, Riyaz, Spicer, James, Brown, Emma, Upadhyay, Sunil, Summers, Yvonne, Gurtler, Jayne, Meza, Luis, Thropay, John
Published in Annals of oncology

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled p...

by Paz-Ares, Luis, Dr, Mezger, Jörg, Prof, Ciuleanu, Tudor E, Prof, Fischer, Jürgen R, MD, von Pawel, Joachim, MD, Provencio, Mariano, Prof, Kazarnowicz, Andrzej, MD, Losonczy, György, Prof, de Castro, Gilberto, MD, Szczesna, Aleksandra, MD, Crino, Lucio, MD, Reck, Martin, MD, Ramlau, Rodryg, Prof, Ulsperger, Ernst, MD, Schumann, Christian, MD, Miziara, Jose Elias A, MD, Lessa, Álvaro E, MD, Dediu, Mircea, MD, Bálint, Beatrix, PhD, Depenbrock, Henrik, MD, Soldatenkova, Victoria, MSc, Kurek, Raffael, MD, Hirsch, Fred R, Prof, Thatcher, Nick, FRCP, Socinski, Mark A, Prof
Published in The lancet oncology

Abstract PD1-04: Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination...

by Mariotti, Veronica, Tang, Shou-Ching, Dillon, Patrick, Montero, Alberto, Poklepovic, Andrew, Melin, Susan, Nuhad, Ibrahim, Nikolinakos, Petros, Kennedy, Eugene, Han, Hyo, Ismail-Khan, Roohi, Bruetman, Daniel, Danciu, Oana, Gilman, Paul, Karaszewska, Boguslawa, Lesniewski-Kmak, Krzysztof, Panella, Timothy, Patel, Dhimant, Suszko-Kazarnowicz, Malgorzata, Volterra, Fabio, Soliman, Hatem
Published in Cancer research (Chicago, Ill.)

Exogenous abscisic acid increases stability of polysomes in embryos of triticale caryopses during germination

by Stanisław, Weidner, Marta, Każarnowicz, Ewa, Frączek, Ryszard, Amarowicz, Magdalena, Karamać
Published in Acta physiologiae plantarum

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial

by Nemunaitis, John, Papai, Zsolt, Lñna, Hervñ, Losonczy, Gyorgy, Forget, Frederic, Chouaid, Christos, Szczesna, Alexandra, Gervais, Radj, Ottensmeier, Christian H, Beck, Joseph, Kazarnowicz, Andrzej, Westeel, Virginie, Debieuvre, Didier, Madroszyk, Anne, Felip, Enriqueta, Limacher, Jean Marc, Quoix, Elisabeth
Published in Journal for immunotherapy of cancer